Maintaining cognitive brain health is a high priority for both people with Parkinson’s disease (PD) and family members. Though many living with Parkinson’s will not develop dementia, mild cognitive issues may emerge in 20 to 50 percent.
Moderated by: Gwyn M. Vernon, M.S.N., R.N., C.R.N.P., Co-Founder and National Director of The Edmond J. Safra Visiting Nurse Faculty Program at Parkinson's Foundation
Led by: Ju Young Shin, Ph.D., A.P.R.N., A.N.P.-C., Assistant Professor of Nursing at the University of Delaware, Edie Simpson, R.N., C.N.R.N., EJS-VNF Host Coordinator, Muhammad Ali Parkinson's Center; Joan Gardner, R.N., B.S.N., Clinical Supervisor, Struthers Parkinson's Center, Park Nicollet Health Services
Connie Marras, M.D., Ph.D. , Associate Professor, Neurology, University of Toronto, Morton and Gloria Shulman Movement Disorders Centre and the Edmond J. Safra Program in Parkinson's Disease, Toronto Western Hospital, Canada
Does summer have you thinking about traveling somewhere new or enjoying the great outdoors? Follow these tips on Parkinson’s disease (PD) and travel, sun safety and heat exhaustion:
Vacations are a big part of living well. Many people choose to travel during summer, but with Parkinson’s there are some extra things to consider before hitting the road. These tips can help you stay safe while you travel:
Safinamide (Xadago) was approved by the Food and Drug Administration (FDA) for treatment of Parkinson’s disease (PD) medication fluctuations. Safinamide is a pill that when absorbed in the bloodstream travels to the brain and affects dopaminergic and non-dopaminergic systems.
This week the FDA approved the drug Pimavanserin (Nuplazid) for the treatment of Parkinson’s disease psychosis. There has been a critical, unmet need for development of better drugs to address hallucinations and psychosis in the setting of Parkinson's disease. We have learned over many years that typical high potency neuroleptic antipsychotic drugs (e.g.